Comparison of overall F1 scores and top Gini scores illustrated stronger signals for genes such as ATRX, BRAF, and TP53. Consequently, it may be that targeting top-contributing genes to classification may offer therapeutic benefits in cancer treatment for patients carrying these driver mutations. This evidence concerns the gene ATRX and cancer.